FCF YoY
-9.00%
OCF YoY
-7.02%
Capex YoY
+14.22%
FCF Conversion Δ
-2 pp
Free cash flow bridge for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: -$1.18B
FCF bridge breakdown for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $13.1B | — |
| Operating Cash Flow | -$1B | -85.2% |
| Capital Expenditure | -$174M | -14.8% |
| Free Cash Flow | $11.9B | — |
- Prior Free Cash Flow$13.1B
- Operating Cash Flow-$1B
- Capital Expenditure-$174M
- Free Cash Flow$11.9B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks0.08% TTM
- Dividend Profile4.13% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.